Topic resource collection
Approved comparison material connected to this topic.
5 resourcesRead both sides
Semaglutide (Ozempic, Wegovy) GLP-1 receptor agonist. Slows gastric emptying, reduces insulin secretion Meta-analysis: 18–24% reduction in fasting insulin, 31% improvement in ovulation (2024 JCEM) 0.5–1.0mg weekly (PCOS trials); …
Before selecting a peptide for PCOS research, match the mechanism to your model's primary phenotype. Insulin resistance, inflammation, or combined metabolic-reproductive dysregulation. Each peptide addresses different pathways, a…
GLP-1 Agonists (Semaglutide, Tirzepatide) Incretin receptor activation → insulin secretion, gastric emptying delay Hyperinsulinemia, androgen excess Strong clinical translation. Phase 3 data in PCOS populations Best for insulin-a…
Tirzepatide Dual GLP-1/GIP agonist. Reduces insulin, slows gastric emptying Strong (Phase 3 RCT, n=412) Insulin-resistant, BMI ≥27 5–15mg weekly SC GI side effects during titration (35% nausea rate) Semaglutide GLP-1 agonist. Imp…
Semaglutide (GLP-1 agonist) GLP-1 receptor activation → enhanced insulin secretion, delayed gastric emptying Moderate. Reduces fasting insulin by 25–35% Caloric deficit via appetite suppression + improved glucose disposal 1.0–2.4…